Richard Bryan Riggsbee Myriad Genetics Inc (MYGN) insider trading activity

Richard Bryan Riggsbee is Chief Financial Officer of MYRIAD GENETICS INC. Currently has a direct ownership of 291,812 shares of MYGN, which is worth approximately $3.98 Million. The most recent transaction as insider was on Dec 01, 2023, when has been sold 30,000 shares (Common Stock) at a price of $19.09 per share, resulting in proceeds of $572,700. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 292K

0% 3M change

0% 12M change

Total Value Held $3.98 Million

Richard Bryan Riggsbee Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 01 2023	SELL Open market or private sale	$572,700 $19.09 p/Share	30,000 Reduced 9.32%	291,812 Common Stock
Nov 01 2023	SELL Open market or private sale	$470,700 $15.69 p/Share	30,000 Reduced 8.53%	321,812 Common Stock
Oct 09 2023	SELL Payment of exercise price or tax liability	$185,163 $15.01 p/Share	12,336 Reduced 3.39%	351,812 Common Stock
Sep 26 2023	SELL Payment of exercise price or tax liability	$72,226 $15.99 p/Share	4,517 Reduced 1.23%	364,148 Common Stock
Mar 24 2023	SELL Payment of exercise price or tax liability	$211,795 $23.72 p/Share	8,929 Reduced 2.36%	368,665 Common Stock
Mar 22 2023	SELL Payment of exercise price or tax liability	$93,335 $22.91 p/Share	4,074 Reduced 1.07%	377,594 Common Stock
Mar 15 2023	BUY Grant, award, or other acquisition	-	43,783 Added 10.29%	381,668 Common Stock
Mar 02 2023	SELL Open market or private sale	$338,250 $22.55 p/Share	15,000 Reduced 4.25%	337,885 Common Stock
Feb 18 2023	SELL Payment of exercise price or tax liability	$217,931 $19.42 p/Share	11,222 Reduced 3.08%	352,885 Common Stock
Jan 20 2023	SELL Open market or private sale	$188,376 $20.04 p/Share	9,400 Reduced 2.52%	364,107 Common Stock
Jan 18 2023	SELL Open market or private sale	$12,006 $20.01 p/Share	600 Reduced 0.16%	373,507 Common Stock
Dec 27 2022	SELL Open market or private sale	$303,000 $15.15 p/Share	20,000 Reduced 5.07%	374,107 Common Stock
Oct 09 2022	SELL Payment of exercise price or tax liability	$242,994 $19.62 p/Share	12,385 Reduced 3.05%	394,107 Common Stock
Sep 26 2022	SELL Payment of exercise price or tax liability	$83,637 $18.41 p/Share	4,543 Reduced 1.11%	406,492 Common Stock
Sep 25 2022	SELL Payment of exercise price or tax liability	$98,365 $18.69 p/Share	5,263 Reduced 1.26%	411,035 Common Stock
Aug 25 2022	SELL Payment of exercise price or tax liability	$76,064 $24.89 p/Share	3,056 Reduced 0.73%	416,298 Common Stock
Aug 15 2022	SELL Bona fide gift	-	2,150 Reduced 0.51%	419,354 Common Stock
Mar 24 2022	SELL Payment of exercise price or tax liability	$226,766 $25.32 p/Share	8,956 Reduced 2.08%	421,504 Common Stock
Mar 22 2022	BUY Grant, award, or other acquisition	-	36,866 Added 7.89%	430,460 Common Stock
Feb 18 2022	SELL Payment of exercise price or tax liability	$287,214 $25.69 p/Share	11,180 Reduced 2.76%	393,594 Common Stock
Feb 16 2022	BUY Grant, award, or other acquisition	-	48,009 Added 10.6%	404,774 Common Stock
Oct 09 2021	SELL Payment of exercise price or tax liability	$382,850 $30.88 p/Share	12,398 Reduced 3.36%	356,765 Common Stock
Sep 26 2021	SELL Payment of exercise price or tax liability	$151,261 $33.31 p/Share	4,541 Reduced 1.22%	369,163 Common Stock
Sep 25 2021	SELL Payment of exercise price or tax liability	$396,622 $33.31 p/Share	11,907 Reduced 3.09%	373,704 Common Stock
Sep 21 2021	BUY Grant, award, or other acquisition	-	66,977 Added 14.8%	385,611 Common Stock

Also insider at

CDNA

CareDx, Inc. Healthcare

Director

RBR